Allogeneic and other innovative chimeric antigen receptor platforms
Clinical Hematology International · 27.09.2024 · 6 (3)
DOI: 10.46989/001c.121404 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Hematology International, online erschienen am 27.09.2024. Verfasst von Andrew P Jallouk und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medicine, Hematology Oncology Vanderbilt University Medical Center. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
By Andrew P Jallouk, Salyka Sengsayadeth & 3 more. Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of hematologic malignancies. All of the CAR T-cell products that are currently FDA-approved are autologous.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medicine, Hematology Oncology Vanderbilt University Medical Center.
ORCID-Profile: Olalekan Oluwole
Zitieren
APA
Jallouk, A. P., Sengsayadeth, S., Savani, B. N., Dholaria, B., & Oluwole, O. (2024). Allogeneic and other innovative chimeric antigen receptor platforms. Clinical Hematology International, 6(3). https://doi.org/10.46989/001c.121404
Vancouver
Jallouk AP, Sengsayadeth S, Savani BN, Dholaria B, Oluwole O. Allogeneic and other innovative chimeric antigen receptor platforms. Clinical Hematology International. 2024;6(3). doi:10.46989/001c.121404
BibTeX
@article{Jallouk2024,
author = {Jallouk, Andrew P and Sengsayadeth, Salyka and Savani, Bipin N and Dholaria, Bhagirathbhai and Oluwole, Olalekan},
title = {Allogeneic and other innovative chimeric antigen receptor platforms},
journal = {Clinical Hematology International},
year = {2024},
volume = {6},
number = {3},
doi = {10.46989/001c.121404}
}
EUVIMED